Oral Solid Dosage Manufacturing Market

Figure 2.1 Executive Summary: Market Landscape

Figure 2.2 Executive Summary: Service(s) Landscape

Figure 2.3 Executive Summary: Recent Expansions

Figure 2.4 Executive Summary: Capacity Analysis

Figure 2.5 Executive Summary: Demand Analysis

Figure 2.6 Executive Summary: Total Cost of Ownership

Figure 2.7 Executive Summary: Market Sizing and Opportunity Analysis

Figure 2.8 Executive Summary: Case Study on Taste Masking Service Providers

Figure 2.9 Executive Summary: Case Study on Bioavailability Enhancement Service Providers

Figure 3.1 Properties of Dosage Forms

Figure 3.2 Types of Dosage Forms

Figure 3.3 Advantages and Disadvantages of Oral Solid Dosage Forms

Figure 3.4 Properties of Pharmaceutical Excipient

Figure 3.5 Type of Oral Solid Dosage Forms

Figure 3.6 Classification of Orally Administered Tablets

Figure 3.7 Tablet Processing Methods

Figure 3.8 Oral Solid Dosage Manufacturing Process

Figure 3.9 Services Offered by CDMOs and CMOs for Oral Solid Dosage

Figure 3.10 Key Considerations While Selecting a CDMO or CMO Partner

Figure 4.1 Oral Solid Dosage Contract Manufacturers: Distribution by Year of Establishment

Figure 4.2 Oral Solid Dosage Contract Manufacturers: Distribution by Company Size

Figure 4.3 Oral Solid Dosage Contract Manufacturers: Distribution by Location of Headquarters

Figure 4.4 World Map Representation: Distribution by Geography

Figure 4.5 Oral Solid Dosage Contract Manufacturers: Distribution by Company Ownership

Figure 4.6 Oral Solid Dosage Contract Manufacturers: Distribution by Types of Service(s) Offered

Figure 4.7 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Finished Dosage Form

Figure 4.8 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Tablet(s) Manufactured

Figure 4.9 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Capsule(s) Manufactured

Figure 4.10 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Multi-particulate(s) Manufactured

Figure 4.11 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Primary Packaging Offered

Figure 4.12 Oral Solid Dosage Contract Manufacturers: Distribution by Scale of Operation

Figure 4.13 Oral Solid Dosage Contract Manufacturers: Distribution by High Potency Drug Manufacturing

Figure 4.14 Oral Solid Dosage Contract Manufacturers: Distribution by Availability of Continuous Manufacturing

Figure 4.15 Oral Solid Dosage Contract Manufacturers: Distribution by Regulatory Certification / Accreditation

Figure 5.1 Company Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers based in the US

Figure 5.2 Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers based in Canada

Figure 5.3 Company Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers Based in the EU5

Figure 5.4 Company Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers Based in Other European Countries

Figure 5.5 Company Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers Based in India

Figure 5.6 Company Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers Based in China

Figure 5.7 Company Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers Based in Japan

Figure 5.8 Company Competitiveness Analysis: Oral Solid Contract Manufacturers Based in Other Asia-Pacific and Rest of the World

Figure 5.9 Competitiveness Analysis of Oral Solid Dosage Contract Manufacturers: Competitiveness Score of Top Service Providers

Figure 6.1 Oral Solid Dosage Contract Manufacturers: Distribution by Location of Manufacturing Facilities

Figure 6.2 Oral Solid Dosage Contract Manufacturing: North America Scenario (I / II)

Figure 6.3 Oral Solid Dosage Contract Manufacturers: North America Scenario (II / II)

Figure 6.4 Oral Solid Dosage Contract Manufacturing: Europe Scenario (I / II)

Figure 6.5 Oral Solid Dosage Contract Manufacturers: Europe Scenario (II / II)

Figure 6.6 Oral Solid Dosage Contract Manufacturing: Asia-Pacific and Rest of the World Scenario (I / II)

Figure 6.7 Oral Solid Dosage Contract Manufacturers: Asia-Pacific and Rest of the World Scenario (II / II)

Figure 7.1 Catalent: Annual Revenues, FY 2017- FY 2022 (USD Billion)

Figure 7.2 Catalent: Distribution of FY 2022 Revenues by Business Segment

Figure 7.3 Aenova: Annual Revenues, FY 2017- FY 2021 (EUR Million)

Figure 7.4 Aenova: Distribution of FY 2021 Revenues by Type of Business Segment

Figure 7.5 Almac: Annual Revenues, FY 2017- FY 2021 (GBP Million)

Figure 7.6 Lonza: Annual Revenues, FY 2017- FY 2022 (CHF Billion)

Figure 7.7 Lonza: Distribution of FY 2022 Revenues by Type of Business Segment

Figure 7.8 Ind-Swift Laboratories: Annual Revenues, FY 2017- FY 2022 (INR Billion)

Figure 8.1 Make versus Buy Decision Making Framework

Figure 8.2 Make versus Buy Decision Making: Possible Scenario Descriptions

Figure 9.1 Recent Expansions: Cumulative Year-wise Trend, 2018-2022

Figure 9.2 Recent Expansions: Distribution by Type of Expansion

Figure 9.3 Recent Expansions: Distribution by Year and Type of Expansion

Figure 9.4 Recent Expansions: Distribution by Type of Oral Solid Dosage Form(s) Involved

Figure 9.5 Recent Expansions: Distribution by Type of Expansion and Oral Solid Dosage Form(s) Involved

Figure 9.6 Recent Expansions: Distribution by Type of Service(s) Offered

Figure 9.7 Recent Expansion: Distribution by Scale of Operation

Figure 9.8 Recent Expansions: Distribution by Location of Facility (Region-wise)

Figure 9.9 Recent Expansions: Distribution by Location of Facility (Country-wise)

Figure 9.10 Expansions Focused on Highly Potent Compounds: Distribution by Type of Expansion

Figure 10.1 Annual Minimum, Average and Maximum Oral Solid Dosage Contract Manufacturing Capacity (Distribution by Company Size: Sample Data Set

Figure 10.2 Distribution by Minimum, Average and Maximum Weight of Various Finished Dosage Forms: Sample Data Set

Figure 10.3 Distribution by Minimum, Average and Maximum Share of API in Various Finished Dosage Forms: Sample Data Set

Figure 10.4 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosage Units): Distribution by Company Size

Figure 10.5 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosage Forms): Distribution by Scale of Operation

Figure 10.6 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosage Forms): Distribution by Type of Finished Dosage Form

Figure 10.7 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Location of Manufacturing Facility): Distribution by Location of Manufacturing Facility

Figure 10.8 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosages): Distribution by Company Size and Type of Finished Dosage Form

Figure 10.9 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosages): Distribution by Company Size and Location of Manufacturing Facility

Figure 10.10 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosages): Distribution by Scale of Operation and Location of Manufacturing Facility

Figure 10.11 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API): Distribution by Company Size

Figure 10.12 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Amount of API): Distribution by Scale of Operation

Figure 10.13 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API): Distribution by Type of Finished Dosage Form

Figure 10.14 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API): Distribution by Company Size and Type of Finished Dosage Form

Figure 10.15 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API): Distribution by Company Size and Location of Manufacturing Facility

Figure 10.16 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API): Distribution by Scale of Operation and Location of Manufacturing Facility

Figure 11.1 Demand Analysis: Annual Outsourced Demand for Oral Solid Doses, 2023-2035 (Metric Ton)

Figure 11.2 Annual Demand for Oral Solid Doses: Distribution by Scale of Operation, 2023 and 2035 (Metric Ton)

Figure 11.3 Annual Outsourced Commercial Demand for Oral Solid Doses, 2023-2035 (Metric Ton)

Figure 11.4 Commercial Outsourced Demand for Oral Solid Doses: Distribution by Geography, 2023 and 2035 (Metric Ton)

Figure 11.5 Commercial Outsourced Demand for Oral Solid Doses in North America, 2023-2035 (Metric Ton)

Figure 11.6 Commercial Outsourced Demand for Oral Solid Doses in Europe, 2023-2035 (Metric Ton)

Figure 11.7 Commercial Outsourced Demand for Oral Solid Doses in Asia-Pacific and Rest of the World, 2023-2035 (Metric Ton)

Figure 11.8 Commercial Outsourced Demand for Oral Solid Doses: Distribution by Therapeutic Area, 2023 and 2035 (Metric Ton)

Figure 11.9 Commercial Outsourced Demand for Oral Solid Doses for Oncological Disorders, 2023-2035 (Metric Ton)

Figure 11.10 Commercial Outsourced Demand for Oral Solid Doses for Infectious Diseases, 2023-2035 (Metric Ton)

Figure 11.11 Commercial Outsourced Demand for Oral Solid Doses for Cardiovascular Disorders, 2023-2035 (Metric Ton)

Figure 11.12 Commercial Outsourced Demand for Oral Solid Doses for Metabolic Disorders, 2023-2035 (Metric Ton)

Figure 11.13 Commercial Outsourced Demand for Oral Solid Doses for Neurological Disorders, 2023-2035 (Metric Ton)

Figure 11.14 Commercial Outsourced Demand for Oral Solid Doses for Genetic Disorders, 2023-2035 (Metric Ton)

Figure 11.15 Commercial Outsourced Demand for Oral Solid Doses for Respiratory Disorders, 2023-2035 (Metric Ton)

Figure 11.16 Commercial Outsourced Demand for Oral Solid Doses for Immunological Disorders, 2023-2035 (Metric Ton)

Figure 11.17 Commercial Outsourced Demand for Oral Solid Doses for Other Disorders, 2023-2035 (Metric Ton)

Figure 11.18 Annual Outsourced Clinical Demand for Oral Solid Doses, 2023-2035 (Metric Ton)

Figure 11.19 Clinical Outsourced Demand for Oral Solid Doses: Distribution by Trial Phase, 2023-2035 (Metric Ton)

Figure 11.20 Clinical Outsourced Demand for Oral Solid Doses in Phase I Trials, 2023-2035 (Metric Ton)

Figure 11.21 Clinical Outsourced Demand for Oral Solid Doses in Phase II Trials, 2023-2035 (Metric Ton)

Figure 11.22 Clinical Outsourced Demand for Oral Solid Doses in Phase III Trials, 2023-2035 (Metric Ton)

Figure 11.23 Annual Outsourced Demand and Capacity Utilization Rate: 2023-2035 (Metric Tons)

Figure 11.24 Oral Solid Dosage Contract Manufacturing: Correlation between Demand and Capacity, 2023-2035

Figure 12.1 Total Cost of Ownership: Types of Capital Expenditures (CapEx)

Figure 12.2 Total Cost of Ownership: Types of Operational Expenditures (OpEx)

Figure 12.3 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations, Y0-Y20 (USD Million)

Figure 12.4 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations: Distribution by CapEx and OpEx, Y0 and Y20 (USD Million)

Figure 12.5 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations: Distribution by CapEx and OpEx, Y0-Y20 (USD Million)

Figure 12.6 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations, Y0: Distribution of CapEx (USD Million)

Figure 12.7 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations, Y0: Distribution of OpEx (USD Million)

Figure 13.1 Key Regulatory Requirements for CMOs and CROs in India

Figure 13.2 Regulatory Landscape for Oral Solid Dosage CMOs: Distribution by Certifications / Accreditations Received

Figure 13.3 Bubble Analysis: Regional Regulatory Summary

Figure 14.1 Taste Masking and Taste Assessment Service Providers: Distribution by Year of Establishment

Figure 14.2 Taste Masking and Taste Assessment Service Providers: Distribution by Company Size

Figure 14.3 Taste Masking and Taste Assessment Service Providers: Distribution by Location of Headquarters

Figure 14.4 Taste Masking and Taste Assessment Service Providers: Distribution by Year of Establishment and Location of Headquarters

Figure 14.5 Taste Masking and Taste Assessment Services: Distribution by Service(s) Offered

Figure 14.6 Taste Masking and Taste Assessment Services: Distribution by Scale of Operation

Figure 14.7 Taste Masking and Taste Assessment Services: Distribution by Other Service(s) Offered

Figure 14.8 Taste Masking and Taste Assessment Services: Distribution by Type of Formulation(s)

Figure 14.9 Taste Masking and Taste Assessment Services: Distribution by End Users

Figure 14.10 Taste Masking and Taste Assessment Services: Distribution by Techniques Used for Taste Masking

Figure 14.11 Taste Masking and Taste Assessment Services: Distribution by Branch of Healthcare

Figure 14.12 Taste Masking and Taste Assessment Services: Distribution by Regional Capability

Figure 15.1 Bioavailability Enhancement Service Providers: Distribution by Year of Establishment

Figure 15.2 Bioavailability Enhancement Service Providers: Distribution by Company Size

Figure 15.3 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Region wise)

Figure 15.4 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Country-wise)

Figure 15.5 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Principle

Figure 15.6 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Approach

Figure 15.7 Bioavailability Enhancement Service Providers: Distribution by Solid Dispersion-based Approaches

Figure 15.8 Bioavailability Enhancement Service Providers: Distribution by Size Reduction Approaches

Figure 15.9 Bioavailability Enhancement Service Providers: Distribution by Lipid-based Approaches

Figure 15.10 Bioavailability Enhancement Service Providers: Distribution by Other Approaches

Figure 15.11 Bioavailability Enhancement Service Providers: Distribution by Dosage Form

Figure 15.12 Bioavailability Enhancement Service Providers: Distribution by Route of Administration

Figure 16.1 Oral Solid Dosage Contract Manufacturing: Market Forecast Approach

Figure 16.2 Global Oral Solid Dosage Contract Manufacturing Market, 2023-2035 (USD Billion)

Figure 16.3 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Type of Finished Dosage Form

Figure 16.4 Tablet Manufacturing Market, 2023-2035 (USD Billion)

Figure 16.5 Capsule Manufacturing Market, 2023-2035 (USD Billion)

Figure 16.6 Powder Manufacturing Market, 2023-2035 (USD Billion)

Figure 16.7 Multi-particulates Manufacturing Market, 2023-2035 (USD Billion)

Figure 16.8 Other Finished Dosage Forms Manufacturing Market, 2023-2035 (USD Billion)

Figure 16.9 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Type of Packaging (USD Billion)

Figure 16.10 Oral Solid Dosage Contract Manufacturing Market for Bottles, 2023-2035 (USD Billion)

Figure 16.11 Oral Solid Dosage Contract Manufacturing Market for Blisters, 2023-2035 (USD Billion)

Figure 16.12 Oral Solid Dosage Contract Manufacturing Market for Inhalers, 2023-2035 (USD Billion)

Figure 16.13 Oral Solid Dosage Contract Manufacturing Market for Sachets, 2023-2035 (USD Billion)

Figure 16.14 Oral Solid Dosage Contract Manufacturing Market for Strips, 2023-2035 (USD Billion)

Figure 16.15 Oral Solid Dosage Contract Manufacturing Market for Stick Packs, 2023-2035 (USD Billion)

Figure 16.16 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Scale of Operation (USD Billion)

Figure 16.17 Oral Solid Dosage Contract Manufacturing Market for Pre-commercial Scale, 2023-2035 (USD Billion)

Figure 16.18 Oral Solid Dosage Contract Manufacturing Market for Commercial Scale, 2023-2035 (USD Billion)

Figure 16.19 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Company Size (USD Billion)

Figure 16.20 Oral Solid Dosage Contract Manufacturing Market for Small Companies, 2023-2035 (USD Billion)

Figure 16.21 Oral Solid Dosage Contract Manufacturing Market for Mid-sized Companies, 2023-2035 (USD Billion)

Figure 16.22 Oral Solid Dosage Contract Manufacturing Market for Large Companies, 2023-2035 (USD Billion)

Figure 16.23 Oral Solid Dosage Contract Manufacturing Market for Very Large Companies, 2023-2035 (USD Billion)

Figure 16.24 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Therapeutic Area (USD Billion)

Figure 16.25 Oral Solid Dosage Contract Manufacturing Market for Oncological Disorders, 2023-2035 (USD Billion)

Figure 16.26 Oral Solid Dosage Contract Manufacturing Market for Infectious Diseases, 2023-2035 (USD Billion)

Figure 16.27 Oral Solid Dosage Contract Manufacturing Market for Cardiovascular Disorders, 2023-2035 (USD Billion)

Figure 16.28 Oral Solid Dosage Contract Manufacturing Market for Metabolic Disorders, 2023-2035 (USD Billion)

Figure 16.29 Oral Solid Dosage Contract Manufacturing Market for Neurological Disorders, 2023-2035 (USD Billion)

Figure 16.30 Oral Solid Dosage Contract Manufacturing Market for Genetic Disorders, 2023-2035 (USD Billion)

Figure 16.31 Oral Solid Dosage Contract Manufacturing Market for Respiratory Disorders, 2023-2035 (USD Billion)

Figure 16.32 Oral Solid Dosage Contract Manufacturing Market for Immunological Disorders, 2023-2035 (USD Billion)

Figure 16.33 Oral Solid Dosage Contract Manufacturing Market for Other Disorders, 2023-2035 (USD Billion)

Figure 16.34 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Key Geographical Regions (USD Billion)

Figure 16.35 Oral Solid Dosage Contract Manufacturing Market in North America, 2023-2035 (USD Billion)

Figure 16.36 Oral Solid Dosage Contract Manufacturing Market in Europe, 2023-2035 (USD Billion)

Figure 16.37 Oral Solid Dosage Contract Manufacturing Market in Asia-Pacific, 2023-2035 (USD Billion)

Figure 16.38 Oral Solid Dosage Contract Manufacturing Market in Latin America, 2023-2035 (USD Billion)

Figure 16.39 Oral Solid Dosage Contract Manufacturing Market in Middle East and North Africa, 2023-2035 (USD Billion)

Table 3.1 Commonly Used Excipients in Tablet Formulation

Table 3.1 Contrasting Characteristics: Film-coated and Sugar-coated Tablets

Table 3.2 Contrasting Characteristics: Hard Gelatin and Soft Gelatin Capsules

Table 4.1 Oral Solid Dosage Contract Manufacturing: List of Companies

Table 4.2 Oral Solid Dosage Contract Manufacturers: Information on Service(s) Offered

Table 4.3 Oral Solid Dosage Contract Manufacturers: Information on Type of Finished Dosage Form Manufactured

Table 4.4 Oral Solid Dosage Contract Manufacturers: Information on Type of Tablets and Capsules Manufactured

Table 4.5 Oral Solid Dosage Contract Manufacturers: Information on Type of Multi-particulate(s) Manufactured

Table 4.6 Oral Solid Dosage Contract Manufacturers: Information on Type of Primary Packaging Offered

Table 4.7 Oral Solid Dosage Contract Manufacturers: Information on Scale of Operation and Additional Manufacturing Capabilities

Table 4.8 Oral Solid Dosage Contract Manufacturers: Information on Regulatory Certifications and Accreditations

Table 6.1 Oral Solid Dosage Contract Manufacturers based in North America: Information on Headquarters, Year of Establishment, Company Size and Additional Manufacturing Capabilities

Table 6.2 Oral Solid Dosage Contract Manufacturers based in North America: Information on Scale of Operation, Type of Dosage Form and Number of Manufacturing Facilities

Table 6.3 Oral Solid Dosage Contract Manufacturers based in Europe: Information on Headquarters, Year of Establishment, Company Size and Additional Manufacturing Capabilities

Table 6.4 Oral Solid Dosage Contract Manufacturers based in Europe: Information Scale of Operation, Type of Dosage Form and Number of Manufacturing Facilities

Table 6.5 Oral Solid Dosage Contract Manufacturers based in Asia-Pacific and Rest of the World: Information on Headquarters, Year of Establishment, Company Size and Additional Manufacturing Capabilities

Table 6.6 Oral Solid Dosage Contract Manufacturers based in Asia-Pacific and Rest of the World: Information on Scale of Operation, Type of Dosage Form and Number of Manufacturing Facilities

Table 7.1 Oral Solid Dosage Contract Manufacturing Service Providers: List of Profiled Companies

Table 7.2 Alcami: Company Snapshot

Table 7.3 Alcami: Service Portfolio

Table 7.4 Alcami: Recent Developments and Future Outlook

Table 7.5 Cambrex: Company Snapshot

Table 7.6 Cambrex: Service Portfolio

Table 7.7 Cambrex: Oral Solid Manufacturing Facilities,

Table 7.8 Cambrex: Recent Developments and Future Outlook

Table 7.9 Catalent: Company Snapshot

Table 7.10 Catalent: Service Portfolio

Table 7.11 Catalent: Oral Solid Manufacturing Facilities

Table 7.12 Catalent: Recent Developments and Future Outlook

Table 7.13 Aenova: Company Snapshot

Table 7.14 Aenova: Service Portfolio

Table 7.15 Aenova: Oral Solid Manufacturing Facilities

Table 7.16 Aenova: Recent Developments and Future Outlook

Table 7.17 Almac: Company Snapshot

Table 7.18 Almac: Service Portfolio

Table 7.19 Almac: Oral Solid Manufacturing Facilities,

Table 7.20 Almac: Recent Developments and Future Outlook

Table 7.21 Lonza: Company Snapshot

Table 7.22 Lonza: Service Portfolio

Table 7.23 Lonza: Oral Solid Manufacturing Facilities

Table 7.24 Lonza: Recent Developments and Future Outlook

Table 7.25 Hetero Drugs: Company Snapshot

Table 7.26 Hetero Drugs: Service Portfolio

Table 7.27 Hetero Drugs: Recent Developments and Future Outlook

Table 7.28 Ind-Swift Laboratories: Company Snapshot

Table 7.29 Ind-Swift Laboratories: Service Portfolio

Table 7.30 Ind-Swift Laboratories: Oral Solid Manufacturing Facilities

Table 7.31 Rubicon Research: Company Snapshot

Table 7.32 Rubicon Research: Service Portfolio

Table 7.33 Rubicon Research: Oral Solid Manufacturing Facilities

Table 9.1 Oral Solid Dosage Contract Manufacturers: List of Recent Expansions, 2018-2022

Table 9.2 Recent Expansions: Information on Type of Oral Solid Dosage Form(s) Involved, Type of Service(s) Offered and Scale(s) of Operation, 2018-2022

Table 10.1 Average Annual Oral Solid Dosage Contract Manufacturing Capacity (Distribution by Type of Finished Dosage Form): Sample Data Set

Table 10.2 Average Annual Oral Solid Dosage Contract Manufacturing Capacity (Distribution by Company Size): Sample Data Set

Table 10.3 Distribution by Amount of API in Various Types of Oral Solid Dosage Forms: Sample Data Set

Table 10.4 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosages): Distribution by Company Size

Table 11.1 Annual Outsourced Demand for Oral Solid Doses, 2023-2035 (Metric Ton)

Table 11.2 Demand and Supply Analysis: Information on Annual Capacity Utilization Rates

Table 11.3 Annual Outsourced Demand (Base and Optimistic Scenarios): 2023-2035 (Metric Tons)

Table 12.1 Total Cost of Ownership: Sample Dataset for CapEx

Table 12.2 Total Cost of Ownership: Sample Dataset for OpEx

Table 13.1 FDA Quality Agreement versus EMA cGMP Regulations: A Comparative Analysis

Table 13.2 Health Canada’s Good Manufacturing Practices Guidelines for Tablets and Capsules

Table 13.3 Oral Solid Dosage CMOs: Information on Approval from Various Regulatory Authorities

Table 13.4 Key Regulatory Authorities: Comparison of NDA Approval Characteristics

Table 14.1 List of Taste Masking and Taste Assessment Service Providers

Table 14.2 Taste Masking and Taste Assessment Services: Information on Service(s) Offered, Scale of Operation and Other Service(s) Offered

Table 14.3 Taste Masking and Taste Assessment Services: Information on Type of Formulation

Table 14.4 Taste Masking and Taste Assessment Services: Information on End Users, Techniques Used for Taste Masking, Branch of Healthcare and Regional Capability

Table 15.1 List of Bioavailability Enhancement Service Providers

Table 15.2 Bioavailability Enhancement Service Providers: Information on Bioavailability Enhancement Principle

Table 15.3 Bioavailability Enhancement Service Providers: Information on Bioavailability Enhancement Approach

Table 15.4 Bioavailability Enhancement Service Providers: Information on Solid Dispersion Approaches

Table 15.5 Bioavailability Enhancement Service Providers: Information on Size Reduction Approaches

Table 15.6 Bioavailability Enhancement Service Providers: Information on Lipid-Based Approaches

Table 15.7 Bioavailability Enhancement Service Providers: Information on Other Approaches

Table 15.8 Bioavailability Enhancement Service Providers: Information on Dosage Form, ,

Table 15.9 Bioavailability Enhancement Service Providers: Information on Route of Administration

Table 17.1 Bushu Pharmaceuticals: Key Highlights

Table 19.1 Oral Solid Dosage Contract Manufacturers: Distribution by Year of Establishment

Table 19.2 Oral Solid Dosage Contract Manufacturers: Distribution by Company Size

Table 19.3 Oral Solid Dosage Contract Manufacturers: Distribution by Location of Headquarters

Table 19.4 Oral Solid Dosage Contract Manufacturers: Distribution by Location of Headquarters (Country-wise)

Table 19.5 Oral Solid Dosage Contract Manufacturers: Distribution by Company Ownership

Table 19.6 Oral Solid Dosage Contract Manufacturers: Distribution by Types of Services Offered

Table 19.7 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Finished Dosage Form

Table 19.8 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Tablet(s) Manufactured

Table 19.9 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Capsule(s) Manufactured

Table 19.10 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Multi-particulate(s)

Table 19.11 Oral Solid Dosage Contract Manufacturers: Distribution by Type of Primary Packaging Offered

Table 19.12 Oral Solid Dosage Contract Manufacturers: Distribution by Scale of Operation

Table 19.13 Oral Solid Dosage Contract Manufacturers: Distribution by High Potency Drug Manufacturing

Table 19.14 Oral Solid Dosage Contract Manufacturers: Distribution by Availability of Continuous Manufacturing

Table 19.15 Oral Solid Dosage Contract Manufacturers: Distribution by Regulatory Certifications and Accreditations

Table 19.16 Catalent: Annual Revenues, FY 2017 – FY 2022 (USD Billion)

Table 19.17 Aenova: Annual Revenues, FY 2017 – FY 2021 (EUR Million)

Table 19.18 Almac: Annual Revenues, FY 2017 – FY 2021 (GBP Million)

Table 19.19 Lonza: Annual Revenues, FY 2017 – FY 2022 (CHF Billion)

Table 19.20 Ind-Swift Laboratories: Annual Revenues, FY 2017 – FY 2022 (INR Billion)

Table 19.21 Recent Expansions: Cumulative Year-wise Trend, 2018-2022

Table 19.22 Recent Expansions: Distribution by Type of Expansion

Table 19.23 Recent Expansions: Distribution by Year and Type of Expansion

Table 19.24 Recent Expansions: Distribution by Type of Oral Solid Dosage Form(s) Involved

Table 19.25 Recent Expansions: Distribution by Type of Expansion and Oral Solid Dosage Form(s) Involved

Table 19.26 Recent Expansions: Distribution by Type of Service(s) Offered

Table 19.27 Recent Expansion: Distribution by Scale of Operation

Table 19.28 Recent Expansions: Distribution by Location of Facility (Region-wise)

Table 19.29 Recent Expansions: Distribution by Location of Facility (Country-wise)

Table 19.30 Expansions Focused on Highly Potent Compounds: Distribution by Type of Expansion

Table 19.31 Annual Global Capacity for Oral Solid Contract Manufacturing (Number of FDF Units): Distribution by Company Size and Range of Installed Capacity

Table 19.32 Average Annual Oral Solid Dosage Contract Manufacturing Capacity (Distribution by Average Weight of Various Finished Dosage Forms): Sample Data Set

Table 19.33 Average Annual Oral Solid Dosage Contract Manufacturing Capacity (Distribution by Share of API in Various Finished Dosage Forms): Sample Data Set

Table 19.34 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosage Units): Distribution by Company Size

Table 19.35 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosage Forms): Distribution by Scale of Operation

Table 19.36 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosage Forms): Distribution by Type of Finished Dosage Form

Table 19.37 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Location of Manufacturing Facility): Distribution by Location of Manufacturing Facility

Table 19.38 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosages): Distribution by Company Size and Type of Finished Dosage Form

Table 19.39 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosages): Distribution by Company Size and Location of Manufacturing Facility

Table 19.40 Installed Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosages): Distribution by Scale of Operation and Location of Manufacturing Facility

Table 19.41 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API Processed): Distribution by Company Size

Table 19.42 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Number of Finished Dosage Forms): Distribution by Scale of Operation

Table 19.43 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API): Distribution by Type of Finished Dosage Form

Table 19.44 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API): Distribution by Company Size and Type of Finished Dosage Form

Table 19.45 Annual Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API): Distribution by Company Size and Location of Manufacturing Facility

Table 19.46 Installed Global Oral Solid Dosage Contract Manufacturing Capacity (in terms of Amount of API): Distribution by Scale of Operation and Location of Manufacturing Facility

Table 19.47 Annual Demand and Capacity Utilization Rate: 2023-2035 (Metric Tons)

Table 19.48 Demand Analysis: Annual Demand for Oral Solid Doses, 2023-2035 (Metric Ton)

Table 19.49 Annual Demand for Oral Solid Doses: Distribution by Scale of Operation, 2023 and 2035 (Metric Ton)

Table 19.50 Annual Commercial Demand for Oral Solid Doses, 2023-2035 (Metric Ton)

Table 19.51 Commercial Demand for Oral Solid Doses: Distribution by Geography, 2023 and 2035 (Metric Ton)

Table 19.52 Commercial Demand for Oral Solid Doses in North America, 2023-2035 (Metric Ton)

Table 19.53 Commercial Demand for Oral Solid Doses in Europe, 2023-2035 (Metric Ton)

Table 19.54 Commercial Demand for Oral Solid Doses in Asia-Pacific and Rest of the World, 2023-2035 (Metric Ton)

Table 19.55 Commercial Demand for Oral Solid Doses: Distribution by Therapeutic Area, 2023 and 2035 (Metric Ton)

Table 19.56 Commercial Demand for Oral Solid Doses for Oncological Disorders, 2023-2035 (Metric Ton)

Table 19.57 Commercial Demand for Oral Solid Doses for Infectious Diseases, 2023-2035 (Metric Ton)

Table 19.58 Commercial Demand for Oral Solid Doses for Cardiovascular Disorders, 2023-2035 (Metric Ton)

Table 19.59 Commercial Demand for Oral Solid Doses for Metabolic Disorders, 2023-2035 (Metric Ton)

Table 19.60 Commercial Demand for Oral Solid Doses for Neurological Disorders, 2023-2035 (Metric Ton)

Table 19.61 Commercial Demand for Oral Solid Doses for Genetic Disorders, 2023-2035 (Metric Ton)

Table 19.62 Commercial Demand for Oral Solid Doses for Respiratory Disorders, 2023-2035 (Metric Ton)

Table 19.63 Commercial Demand for Oral Solid Doses for Immunological Disorders, 2023-2035 (Metric Ton)

Table 19.64 Commercial Demand for Oral Solid Doses for Other Disorders, 2023-2035 (Metric Ton)

Table 19.65 Annual Clinical Demand for Oral Solid Doses, 2023-2035 (Metric Ton)

Table 19.66 Clinical Demand for Oral Solid Doses: Distribution by Trial Phase, 2023-2035 (Metric Ton)

Table 19.67 Clinical Demand for Oral Solid Doses in Phase I Trials, 2023-2035 (Metric Ton)

Table 19.68 Clinical Demand for Oral Solid Doses in Phase II Trials, 2023-2035 (Metric Ton)

Table 19.69 Clinical Demand for Oral Solid Doses in Phase III Trials, 2023-2035 (Metric Ton)

Table 19.70 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations, Y0-Y20 (USD Million)

Table 19.71 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations: Distribution by CapEx and OpEx, Y0 and Y20 (USD Million)

Table 19.72 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations: Distribution by CapEx and OpEx, Y0-Y20 (USD Million)

Table 19.73 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations, Y0: Distribution of CapEx (USD Million)

Table 19.74 Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations, Y0: Distribution of OpEx (USD Million)

Table 19.75 Taste Masking and Taste Assessment Service Providers: Distribution by Year of Establishment

Table 19.76 Taste Masking and Taste Assessment Service Providers: Distribution by Company Size

Table 19.77 Taste Masking and Taste Assessment Service Providers: Distribution by Location of Headquarters

Table 19.78 Taste Masking and Taste Assessment Service Providers: Distribution by Year of Establishment and Location of Headquarters

Table 19.79 Taste Masking and Taste Assessment Services: Distribution by Service(s) Offered

Table 19.80 Taste Masking and Taste Assessment Services: Distribution by Scale of Operation

Table 19.81 Taste Masking and Taste Assessment Services: Distribution by Other Service(s) Offered

Table 19.82 Taste Masking and Taste Assessment Services: Distribution by Type of Formulation(s)

Table 19.83 Taste Masking and Taste Assessment Services: Distribution by End Users

Table 19.84 Taste Masking and Taste Assessment Services: Distribution by Techniques Used for Taste Masking

Table 19.85 Taste Masking and Taste Assessment Services: Distribution by Branch of Healthcare

Table 19.86 Taste Masking and Taste Assessment Services: Distribution by Regional Capability

Table 19.87 Bioavailability Enhancement Service Providers: Distribution by Year of Establishment

Table 19.88 Bioavailability Enhancement Service Providers: Distribution by Company Size

Table 19.89 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Region-wise)

Table 19.90 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Country-wise)

Table 19.91 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Principle

Table 19.92 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Approach

Table 19.93 Bioavailability Enhancement Service Providers: Distribution by Solid Dispersion-based Approaches

Table 19.94 Bioavailability Enhancement Service Providers: Distribution by Size Reduction Approaches

Table 19.95 Bioavailability Enhancement Service Providers: Distribution by Lipid-based Approaches

Table 19.96 Bioavailability Enhancement Service Providers: Distribution by Other Approaches

Table 19.97 Bioavailability Enhancement Service Providers: Distribution by Dosage Form

Table 19.98 Bioavailability Enhancement Service Providers: Distribution by Route of Administration

Table 19.99 Global Oral Solid Dosage Contract Manufacturing Market, 2023-2035 (USD Billion)

Table 19.100 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Type of Finished Dosage Form

Table 19.101 Tablet Manufacturing Market, 2023-2035 (USD Billion)

Table 19.102 Capsule Manufacturing Market, 2023-2035 (USD Billion)

Table 19.103 Powder Manufacturing Market, 2023-2035 (USD Billion)

Table 19.104 Multi-particulates Manufacturing Market, 2023-2035 (USD Billion)

Table 19.105 Other Finished Dosage Forms Manufacturing Market, 2023-2035 (USD Billion)

Table 19.106 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Type of Packaging

Table 19.107 Oral Solid Dosage Contract Manufacturing Market for Bottles, 2023-2035 (USD Billion)

Table 19.108 Oral Solid Dosage Contract Manufacturing Market for Blisters, 2023-2035 (USD Billion)

Table 19.109 Oral Solid Dosage Contract Manufacturing Market for Inhalers, 2023-2035 (USD Billion)

Table 19.110 Oral Solid Dosage Contract Manufacturing Market for Sachets, 2023-2035 (USD Billion)

Table 19.111 Oral Solid Dosage Contract Manufacturing Market for Strips, 2023-2035 (USD Billion)

Table 19.112 Oral Solid Dosage Contract Manufacturing Market for Stick Packs, 2023-2035 (USD Billion)

Table 19.113 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Scale of Operation

Table 19.114 Oral Solid Dosage Contract Manufacturing Market for Pre-commercial Scale, 2023-2035 (USD Billion)

Table 19.115 Oral Solid Dosage Contract Manufacturing Market for Commercial Scale, 2023-2035 (USD Billion)

Table 19.116 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Company Size

Table 19.117 Oral Solid Dosage Contract Manufacturing Market for Small Companies, 2023-2035 (USD Billion)

Table 19.118 Oral Solid Dosage Contract Manufacturing Market for Mid-sized Companies, 2023-2035 (USD Billion)

Table 19.119 Oral Solid Dosage Contract Manufacturing Market for Large Companies, 2023-2035 (USD Billion)

Table 19.120 Oral Solid Dosage Contract Manufacturing Market for Very Large Companies, 2023-2035 (USD Billion)

Table 19.121 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Therapeutic Area

Table 19.122 Oral Solid Dosage Contract Manufacturing Market for Oncological Disorders, 2023-2035 (USD Billion)

Table 19.123 Oral Solid Dosage Contract Manufacturing Market for Infectious Diseases, 2023-2035 (USD Billion)

Table 19.124 Oral Solid Dosage Contract Manufacturing Market for Cardiovascular Disorders, 2023-2035 (USD Billion)

Table 19.125 Oral Solid Dosage Contract Manufacturing Market for Metabolic Disorders, 2023-2035 (USD Billion)

Table 19.126 Oral Solid Dosage Contract Manufacturing Market for Neurological Disorders, 2023-2035 (USD Billion)

Table 19.127 Oral Solid Dosage Contract Manufacturing Market for Genetic Disorders, 2023-2035 (USD Billion)

Table 19.128 Oral Solid Dosage Contract Manufacturing Market for Respiratory Disorders, 2023-2035 (USD Billion)

Table 19.129 Oral Solid Dosage Contract Manufacturing Market for Immunological Disorders, 2023-2035 (USD Billion)

Table 19.130 Oral Solid Dosage Contract Manufacturing Market for Other Disorders, 2023-2035 (USD Billion)

Table 19.131 Oral Solid Dosage Contract Manufacturing Market, 2023 and 2035: Distribution by Geographical Regions (USD Billion)

Table 19.132 Oral Solid Dosage Contract Manufacturing Market in North America, 2023-2035 (USD Billion)

Table 19.133 Oral Solid Dosage Contract Manufacturing Market in Europe, 2023-2035 (USD Billion)

Table 19.134 Oral Solid Dosage Contract Manufacturing Market in Asia-Pacific, 2023-2035 (USD Billion)

Table 19.135 Oral Solid Dosage Contract Manufacturing Market in Latin America, 2023-2035 (USD Billion)

Table 19.136 Oral Solid Dosage Contract Manufacturing Market in Middle East and North Africa, 2023-2035 (USD Billion)

Please reach out to our team for more details.